DTI Drug Target Insights 2025; 19: 11-17 ISSN 1177-3928 | DOI: 10.33393/dti.2025.3271 ORIGINAL RESEARCH ARTICLE Drug Target Insights - ISSN 1177-3928 - www.aboutscience.eu/dti © 2025 The Authors. This article is published by AboutScience and licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Commercial use is not permitted and is subject to Publisher’s permissions. Full information is available at www.aboutscience.eu Exploring the in vitro anti-diabetic potential and in silico studies of 2, 3 and 2, 6-dichloroIndolinone Abdur Rauf 1, Waqas Alam 1, Momin Khan2, Hany W. Darwish3, Maria Daglia 4, Ahmed A. Elhenawy 5, Haroon Khan 1,6 1Department of Pharmacy, Abdul Wali Khan University, Mardan - Pakistan 2Department of Chemistry, Abdul Wali Khan University, Mardan - Pakistan 3Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh - Kingdom of Saudi Arabia 4Department of Pharmacy, University of Naples Federico II- Italy 5Department of Chemistry, Faculty of Science, Al-Azhar University, Cairo - Egypt 6Department of Pharmacy, Korea University, Sejong - South Korea ABSTRACT Introduction: Adequate hyperglycemic control is still a huge challenge with the clinically used therapeutics. New, more effective anti-diabetic agents are on the top list of drug discovery projects. Methods: This article deals with the in vitro anti-diabetic potential of 2, 3 dichloroIndolinone (C1) and 2, 6-dichlo- roIndolinone (C2) on α-glucosidase and α-amylase followed by in silico analysis. Results: Both compounds, C-1 and C-2, caused significant inhibition of α-glucosidase at various test concentra- tions with IC50 of 35.266 μM and 38. 379 μM, respectively. Similarly, compounds C-1 and C-2 elicited significant anti-α-amylase action with IC50 values of 42.449 μM and 46.708 μM, respectively. The molecular docking investi- gation regarding the α-glucosidase and α-amylase binding site was implemented to attain better comprehension with respect to the pattern in which binding mechanics occur between the C1 and C2 molecules and the active sites, which illustrated a higher binding efficacy in appraisal with reference inhibitor and acarbose. The interac- tions between the active compounds C1 and C2 with the active site residues were mainly polar bonds, hydro- gen bonding, π−π, and π−H interactions, which contributed to a strong alignment with the enzyme backbone. Similarly, effective binding is frequently indicated by a strong and stable hydrogen-bonding pattern, which is sug- gested by the minimal fluctuation in MM-PBSA values. Conclusion: In short, this study will contribute to providing these compounds with an improved anti-diabetic profile and decreased toxicity. Keywords: 2, 3 and 2, 6-dichloroIndolinone, α-glucosidase/α-amylase inhibition, Molecular docking, Molecular simulation Received: August 23, 2024 Accepted: February 4, 2025 Published online: March 10, 2025 Corresponding author: Haroon Khan email: haroonkhan@awkum.edu.pk by type II DM (T2DM), which is described by tissue inadequate insulin or insulin resistance synthesis by the pancreatic β cells and an improper compensatory insulin secretory response (2). Diabetes is the tenth most common cause of death, accounting for over a million deaths annually. By 2030, the number of people with type 2 diabetes worldwide is expected to reach 7079 per 100,000, indicating a persistent increase in cases worldwide. Concerning evidence indicates that preva- lence is on the rise in lower-income nations. There is a need for immediate clinical preventative and public health actions. (3). Type 2 diabetes, which develops in adult age, is defined by inadequate insulin production, either alone or in combina- tion with insulin resistance (4). There are some key similarities between heart disease [cardiovascular disease (CVD)] and DM. One significant and unique risk factor for CVD is diabetes. The most frequent and expensive blood vessel consequence of dia- betes is heart disease [coronary heart disease (CHD)] (5). There are presently no effective medications to treat this health con- dition, and the available therapies are successful for some Introduction Diabetes mellitus (DM) is a prolonged metabolic state that can result from reduced insulin synthesis or decreased insulin’s ability to facilitate the absorption of glucose. Hyperglycemia or extremely high blood glucose, and glucose intolerance are characteristics of DM (1). The World Health Organization (WHO) describes DM as a life-long metabolic disorder marked by increased blood glucose levels that eventually cause harm to the kidneys, eyes, nerves, cardiovascular system, and vascu- lar system. Over ninety percent of the cases of DM are caused https://doi.org/10.33393/dti.2025.3271 https://creativecommons.org/licenses/by-nc/4.0/legalcode https://orcid.org/0009-0009-4680-4956 https://orcid.org/0009-0009-4680-4956 https://orcid.org/0009-0009-4680-4956 https://orcid.org/0009-0009-4680-4956 https://orcid.org/0009-0009-4680-4956 mailto:haroonkhan%40awkum.edu.pk?subject= Anti-diabetic effects of dichloroindolinone12 © 2025 The Authors. Drug Target Insights - ISSN 1177-3928 - www.aboutscience.eu/dti people but not all. Innovative anti-diabetic drugs are therefore greatly needed. Diabetes management requires an extensive review of current pharmacotherapies and phytotherapies, as well as nutraceutical-based therapies for effective manage- ment of diabetes, along with their merits and limitations (6). The first known oxindole derivative was discovered in the form of alkaloids from the bark of the tropical climber spe- cies known as cat claw’s plant (Uncaria tomentosa), which is native to the dense rainforests of the Amazon region and other tropical regions of central and southern South America (7). Oxindoles are naturally occurring aromatic chemical compounds found in a variety of plant materials as well as in animal tissues and body fluids. A six-membered benzene ring and a five-membered ring containing nitrogen combine to form an oxindole (8). Several researchers have discovered, produced, generated, and analyzed oxindole derivatives for a range of biological effects and observed significant effects (9-12). Medicinal chemists are motivated to create new oxin- dole derivatives because of the oxindole nucleus’s historical and current medicinal value. Oxindole-derived compounds are potent inhibitors of the α-glucosidase enzyme, which is a target enzyme in the treatment of DM (13). The breakdown and intestinal absorption of carbohydrates occur by impor- tant enzymes α-amylase and α-glucosidase, respectively. The therapy of non-insulin-dependent DM (NIDDM) can benefit greatly from the inhibition of these enzymes, which inhibits the rise in blood glucose levels following the consumption of carbohydrates (14). Similarly, 2, 3 and 2, 6-dichloroIndoli- none have already shown potential drug-like properties cou- pled with antioxidant potential (15). In the present article, we are presenting the in vitro α-glucosidase and α-amylase activities of oxindoles, 2, 3 dichloroIndolinone (C1) and 2, 6-dichloroIndolinone (C2) (Figure 1) followed by molecular docking and molecular dynamic simulation. Materials and Methods Chemicals Chemicals used were α-glucosidase, α-amylase, acarbose, glucopyranoside, phosphate buffer, and piperidine, Na2CO3, starch and dinitro salicylic acid -solution, hydrochloric acid and distilled water. α-Glucosidase Activity In this test, Glucopyranoside is incorporated into the sol- vent (phosphate buffer). Several doses of the synthesized compounds, including 62.5 µg/mL, 125 µg/mL, 250 µg/mL, 500 µg/mL, and 1000 µg/mL, were used to create the sam- ple solutions. Added 0.5 µg/mL of glucosidase in distilled water to the mixture described above. Subsequently, the resultant mixture was incubated at 37°C for 20 minutes (16). Hydrochloric acid was used to stop the reaction mixture after the incubation period. Using a spectrophotometer, the color intensity was determined at a wavelength of 540 nm. The percentage inhibition was computed using the following equation: Inhibition (%) = (Control Abs − Test Abs/Control Abs) × 100 α-Amylase Activity In this assay, previously published techniques were applied (16). α-amylase, phosphate buffer, and the sample solu- tion were prepared by combining different amounts of the produced compounds (62.5 µg/mL, 125 µg/mL, 250 µg/mL, 500 µg/mL, and 1000 µg/mL). After mixing this solution with the starch solution, the mixture was left to incubate for around 20 minutes at 37°C. Following incubation, the reac- tant mixture was just maintained at 100°C in a water bath. At 656 nm, the color intensity was determined using a micro- plate reader. The following formula was used to get the inhi- bition percentage. Inhibition (%) = (Control Abs - Test Abs/Control Abs) x 100 Molecular Docking The synergistic effect of characteristics of active com- pounds C1 and C2 on α-glucosidase and α-amylase inhibitory actions was investigated using molecular docking studies (17). The protein data bank provided the α-glucosidase and α-amylase PDB IDs, which are 5NN5 and 4GQR, respectively. Molecular Dynamic Simulation We calculated the parameters, including binding free energy, van der Waals energy, electrostatic energy, kinetic energy, and potential energy changes using molecular dynamics simulations. Furthermore, we investigated the interactions that these compounds had with the proteins, glucosidase, and amylase throughout a time span of 0 to 250 ns. The binding free energy change values for the two compounds interacting with the proteins were also com- puted (18). The docking analysis was performed to explicate the potency of these desirable molecules in vitro against the epidermal growth factor receptor (EGFR) kinase through their potential interaction mechanisms with their crystal frameworks (PDB: 1b2y (19), PDB: 3A4A) (20) ). The dock- ing investigation was implemented through Glide’s module®. The preliminary inhibitors (Acarbose) were relocked into the α-amylase crystal framework to verify the docking meth- odology. Furthermore, the efficacious performance of the targeted molecules was authenticated via the low values of RMSD (1.02 respectively), which were acquired through the FIGURE 1 - Structures of test compounds. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/salicylic-acid Rauf et al Drug Target Insights 2025; 19: 13 © 2025 The Authors. Published by AboutScience - www.aboutscience.eu root mean square deviation between the native and relocked poses of the co-crystallized inhibitor. Statistical Analysis The data is illustrated as mean ± SEM of three distinct measurements. Analyisis of variance (ANOVA) at *p < 0.05 and the Bonferroni test showed static significance using GraphPad version 8. Results Effects of Compounds on α-glucosidase Inhibition Figure 2 shows the α-glucosidase inhibition of selected compounds (C1-C2) when studied at various concentra- tions. In the assay, C1 produced marked inhibition that was increased with increasing drug concentrations, and the maxi- mum effect (88%) was noted at 1000 μM. The IC50 value of C1 was estimated as 35.266 μM. Similarly, C2 displayed signifi- cant α-glucosidase inhibition when tested at various concen- trations. The maximum inhibitory effect was 85% at a dose of 1000 μM in specified conditions. The potency was expressed as an IC50 value of 38.379 μM. In comparison, acarbose had IC50 values of 34.216 μM. Effect of Compounds on α-amylase Inhibition The α-amylase inhibitory potential of test compounds (C1-C2) when challenged at various concentrations are dis- played in Figure 3. Compound 1 caused significant inhibition of α-amylase, and the overall effects were concentration dependant. The maximum inhibition of 90% was observed at FIGURE 2 - Showing α-glucosidase inhibiting effects of Compounds (C1 and C2). The mean ± SEM of three distinct measurements was pro- vided as the result. ANOVA at *p < 0.05 and the Bonferroni test showed static significance. At the same tested strengths, there are slight variations in ***p < 0.001 results when compared to the positive control (Acarbose). FIGURE 3 - Showing α-Amylase inhibiting effects of Compounds (C1 and C2). The Mean ± SEM of three distinct measurements was provided as the result. ANOVA at *p < 0.05 and the Bonferroni test showed static significance. At the same tested strengths, there are slight variations in ***p < 0.001 results when compared to the positive control (Acarbose). Anti-diabetic effects of dichloroindolinone14 © 2025 The Authors. Drug Target Insights - ISSN 1177-3928 - www.aboutscience.eu/dti 1000 μM, and the IC50 was 42.449 μM. Similarly, compound 2 caused potential α-amylase inhibition at various doses from 62.50-1000 μM. The maximum inhibition, 87%, was demon- strated at 1000 μM. The overall effect of IC50 was 46.708 μM. The standard drug (Acarbose) had an IC50 value of 24.802 μM. Molecular Docking Analysis The binding free energies for ΔE are listed in (Table 1). The initial inhibitors have been adequately installed into their binding sites in order to attain their crystal configurations. TABLE 1 - The binding affinity for compounds C1 and C2 with dock- ing score (kcal/mol) against α-amylase No. ΔG RMSD H. B EInt. Eele LE α-glucosides C1 −5.898 0.893 −10.228 −6.188 −13.702 −6.604 C2 −6.312 1.285 −8.658 −4.223 −21.775 −4.912 Acarbose −6.088 0.725 −15.129 −12.148 −31.340 −8.393 α-amylase C1 −5.449 0.955 24.364 −19.256 −8.526 2.10 C2 −5.497 1.257 19.021 −18.133 −8.679 2.253 Acarbose −9.814 1.634 -34.746 −15.117 −55.322 2.885 Where ΔG: Free binding energy of the ligand; RMSD: root-mean-square de- viation; H.B.: H-bonding energy between protein and ligand; EInt. Binding affinity of H-bond interaction with receptor; Eele: Electrostatic interaction over the receptor, Ki: inhibition constant. For the docking analysis, we selected the most perforable docking conformations of C1 and C2 compounds that were detected inside the active site of α-glucosidase enzyme (PDB: 3A4A) with proper alignment. The active site includes the hydrophilic amino acids (ASP69, TYR72, GLU277, HIS351, ASP352, and ARG442), which interact with competitive inhibitor acarbose. We noticed that almost all investigated compounds interacted with significant residues in the bind- ing pocket. We defined the inhibitory behavior in terms of binding energy BE that was evaluated with the receptor. Then, redocked compounds compared the results to the comparative reference inhibitor and obtained a root mean square deviation (RMSD), which is summarized in (Table 1). The C2 exhibited strong interactions with the enzyme, as indicated by their binding free energies of −6.312 Kcal/mol. Compared to the reference inhibitor, which had a binding free energy of −6.088 Kcal/mol and lower inhibitory activity, the C1 showed superior binding efficacies, −5.898 Kcal/mol. The docking analysis revealed that C2 had the highest bind- ing affinity and formed a strong hydrogen bond with Gly353, Glu411, and ASP307, which are essential for enzyme activity. The second inhibitor, C1, had a similar binding mode to the reference inhibitor and established a strong hydrogen bond with GLn353, ARG213, and Gln182 (Figure 4). The molecule docked prolifically into active sites in a mechanism similar to that of the original inhibitors. For amy- lase, compounds C1 and C2 demonstrated promising binding affinities (ΔE = −5.44 to −5.5 kcal/mol), which substantiated their promising potencies. The interactions between the thirteen active compounds C1 and C2 with the active site res- idues were mainly polar bonds, hydrogen bonding, π−π, and π−H interactions, which contributed to a strong alignment with the enzyme backbone Figure 5. The active molecules C1 and C2 were attached deeply and comfortingly in the binding pocket by interacting with the hydrophilic Asp 198 hydropho- bic binding pocket ALA197 and Ile 235. Compound C2 docked in the α-amylase binding pocket via hydrophobic interac- tion with Ala198. It is inferred that the formation of strong interactions with important residues can pinpoint α-amylase in the binding pocket. Lastly, according to the 3D-molecular docking, the C2 prefers a parallel orientation between the central indoline ring and the important hydrophilic Asp 197 into the binding pockets. Molecular Dynamic Investigations of C1-C2 In order to comprehend enzymatic activity and create inhib- itors, it is essential to investigate ligand-enzyme interactions, like the one that exists between the α-glucosidase protein and a ligand. Molecular Mechanics-Poisson-Boltzmann Surface Area (MM-PBSA) computations offer a thorough understand- ing of the molecular binding processes. The dynamic nature of molecular interactions is captured through a rigorous approach of accounting for the flexibility of α-glucosidase FIGURE 4 - Showing 3D Docking poses of C1, and C2 against α- glu- cosidase. FIGURE 5 - Showing 3D Docking poses of C1, and C2 against α- amy- lase. Rauf et al Drug Target Insights 2025; 19: 15 © 2025 The Authors. Published by AboutScience - www.aboutscience.eu protein complexes during contact tests at 2 ns intervals. The energy changes in Figure 6, which illustrate fluctuations in the binding free energy at 12-ns intervals, provide important infor- mation about the strength and stability of the binding through- out time. The significance of structural variations on binding affinity is highlighted by comparing the energy changes of the two dichloroindolinone molecules. Positive interactions were indicated by the binding parameter values that are negative, which is encouraging for the possible effectiveness of these compounds as inhibitors. Effective binding is frequently indi- cated by a strong and stable hydrogen-bonding pattern, which is suggested by the minimal fluctuation in MM-PBSA values. It is unsuitable for illustrating the relationship between molecular docking computations and ligand-protein inter- actions at the ns level since the ligand molecules are rather flexible in the calculations. The ligand-amylase protein inter- action is performed at 250 ns using MM-PSBA calculations. In MM-PSBA calculations, all compounds of amylase protein complexes have flexibility when checking the interaction every 2 ns, and the energy change is reported in Figure 7. The resulting graph in Figure 7 depicts the binding free energy changes and variations in all ten (ns) intervals. The energy changes of the most active two 2, 3 and 2, 6-dichloroIndoli- none molecules were compared, and the calculations were performed to validate the determination of bonding free energies using the molecular MMPBSA approach. Negative values for the relevant parameters indicate improved bind- ing. The small fluctuations for MM-PBSA for both complexed with amylase over the entire time scale indicated a robust contact between Ligand and amino acid backbone, indicating a firm H-bonding pattern. Discussion The study revealed significant in vitro α-glucosidase and α-amylase inhibition of oxindoles, 2, 3 dichloroIndolinone (C1) and 2, 6-dichloroIndolinone (C2), which were molecular docking and simulation studies. The development of a new, more effective molecule with lower toxicity is always a primary target in research (21). Dichloroindolinone are oxindole derivatives that are utilized for a wide range of biological effects (10,22,23). Enzymes belonging to the glucosidases are present on the brush boundary surface of intestinal microglia. They cause starch 1,4-glycosidic bonds to break, releasing –D-glucose, which is absorbed. It consequently raises post-meal hyperglyce- mia. Therefore, it is essential to use these enzyme inhibitors in the management of type II diabetes. A class of enzymes known as α-glucosidases hydrolyzes the 1, 4-glycosidic bond in starch to produce α-D-glucose, which enters the blood- stream after absorption (24). As a result, it causes post-meal hyperglycemia. As a result, using these enzyme inhibitors is essential for managing T2DM. Proper absorption and diges- tion of monosaccharides may help avoid diabetes, obesity, hyperlipoproteinemia, and hyperlipidemia (25). These inhibi- tors may be used to treat malignancies, viral infections, and several other diseases, as well as to regulate the immune system (13). The early metabolism abnormality that arises in NIDDM, postprandial hyperglycemia, has been identified as a potential therapy for glucosidase (26). Our finding on the test compounds showed significant inhibition of the enzyme by both compounds and, therefore, could be potential candi- dates as glucosidase inhibitors. The hydrolase enzyme α-amylase catalyzes the hydrolysis of internal -1, 4-glycosidic bonds in starch to create products like glucose and maltose. Since it is a calcium metalloen- zyme, a metal cofactor is necessary for it to function (27). The class of enzymes known as amylases is responsible for hydrolyzing starch to produce low-molecular-weight dextrins and sugars, and they are crucial for the digestion of carbo- hydrates. Maltose, maltotriose, and other - (1,6) and - (1,4) oligoglucans can be broken down into glucose by various α-glucosidases and are the primary components of the final hydrolysate. Controlling the activity of HPA, which is a human pancreatic enzyme that is essential for the digestion of starch, could effectively lower blood glucose levels after meals (28). When combined, α-glucosidase and α-amylase inhibition can significantly reduce the rise in blood glucose that occurs after meals and could be an essential strategy for controlling blood glucose levels in people with T2DM. The main treatment tar- gets for type-2 DM are thus pancreatic α-amylase and gut glucoamylases. Amylase antagonists are already available on FIGURE 6 - The values of the test compounds C1 and C2 for the Gibbs free energy of ligand α-glucosidase protein. FIGURE 7 - The values of the test compounds C1 and C2 for the Gibbs free energy of ligand α-amylase protein. Anti-diabetic effects of dichloroindolinone16 © 2025 The Authors. Drug Target Insights - ISSN 1177-3928 - www.aboutscience.eu/dti the market for the treatment of diabetes. Amylase inhibitors can also be used to treat obesity (29). We observed strong inhibition of the α-amylase by the test compounds at various concentrations and therefore augmented the overall anti- diabetic potential of these compounds as strong candidates for further studies. Molecular docking tests revealed that the best- ranked conformation of the test compounds fit into the site of activity well, and its oxindole moiety interacted with impor- tant locations in the binding pocket. The interaction between ligands and enzymes was studied in docking investigations to gain a greater understanding of the in vitro outcomes. The structure data for the selected enzymes was obtained by searching the Protein Data Bank. The PDB IDs for α- Amylase and α-Glucosidase were 4GQR and 5NN5, respectively (28, 30). The process and enzyme preparation were completed with the aid of the Molecular Operating Environment (MOE) software. The enzymes were first removed from non-standard structures and inadequate bounded ligands in order to pre- pare them for docking in PDB format. Binding energies were investigated, and docking method outcomes were evalu- ated. It was demonstrated that the optimal ligand-enzyme interaction model produced increased negative values; the more negative values, the greater the probability of binding at that particular site. Various situations were used in order to see the key interaction between the ligands and enzymes, amino acid residues, binding pocket, and bond lengths were presented in different colors. The lowest score poses, and RMSD revealed increased stability in the binding pocket. The data was utilized to rank the docked poses and to select the most capable docked conformation of each compound. The hetero ring for Erlotinib and benzimidazole centered on the α-amylase pocket and interacted with HIS 305, ASP 300, AlA198, ASP 197, THR 163, LEU162, TYR 151, GLN 63, TRP 59. In the MM-PBSA calculations, the ligand-glucosidase and amylase protein interaction is monitored every 2 ns. The negative values indicate improved binding (more favorable interactions). The small fluctuations observed for MM-PBSA over the entire time scale suggest a stable interaction. The robust contact between the ligand and the amino acid back- bone indicates firm hydrogen bonding. Conclusion In a dose-dependent way, the 6-chlorooxindole-derived compounds C1 and C2 showed potential in vitro α-glucosidase and α-amylase inhibition. C1 and C2 demonstrated a high binding and inhibitory potential when docked with the enzyme α-Glucosidase (5NN5) and α-amylase (4GQR) enzyme. Strong alignment with the enzyme backbone was achieved by the active chemicals C1 and C2 interacting primarily with the active site residues through polar bonds, hydrogen bond- ing, π−π, and π−H interactions. The minimal fluctuation in MM-PBSA values suggests a consistent and strong hydrogen- bonding pattern, which is often a hallmark of effective binding. The present investigation reveals improved anti-diabetic fea- tures for the 6-chlorooxindole derivatives. These focused com- pounds could help develop more potent antihyperglycemic medications in the future, but need further detailed studies. Acknowledgments The authors extend their appreciation to the Researchers Supporting Project number (RSPD2025R812), King Saud University, Riyadh, Saudi Arabia, for funding. Disclosures Financial support: The authors extend their appreciation to the Researchers Supporting Project number (RSPD2025R812), King Saud University, Riyadh, Saudi Arabia, for funding. Conflict of Interest: The authors of this article declare no conflict of interest. Data Availability Statement: The data that support the findings of the present study are available from the corresponding authors upon reasonable request. References 1. Sagbo IJ, van de Venter M, Koekemoer T, et al. In vitro anti- diabetic activity and mechanism of action of Brachylaena elliptica (Thunb.) DC. Evidence-Based Complementary and Alternative Medicine, 2018. CrossRef PubMed 2. Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275. CrossRef PubMed 3. Khan MAB, Hashim MJ, King JK, et al. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107-111. CrossRef PubMed 4. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insu- lin at diagnosis (latent autoimmune diabetes of the adult): def- inition, characterization, and potential prevention. Diabetes Care. 2001;24(8):1460-1467. CrossRef PubMed 5. Resnick HE, Howard BV. Diabetes and cardiovascular dis- ease. Annu Rev Med. 2002;53(1):245-267. CrossRef PubMed 6. Khursheed R, Singh SK, Wadhwa S, et al. Treatment strategies against diabetes: success so far and challenges ahead. Eur J Pharmacol. 2019;862:172625. CrossRef PubMed 7. Khetmalis YM, Shivani M, Murugesan S, et al. Oxindole and its derivatives: a review on recent progress in biological activities. Biomed Pharmacother. 2021;141:111842. CrossRef PubMed 8. Gassman PG, Van Bergen T. General method for the synthesis of oxindoles. J Am Chem Soc. 1973;95(8):2718-2719. CrossRef 9. Mukhliss L, Taha M, Rahim F, et al. Synthesis and novel struc- tural hybrid analogs of oxindole derivatives bearing piperi- dine ring, their antidiabetics II activity and molecular docking study. J Mol Struct. 2025;1332:141666. CrossRef 10. Pirzada AS, Khan H, Alam W, et al. Physicochemical proper- ties, pharmacokinetic studies, DFT approach, and antioxidant activity of nitro and chloro indolinone derivatives. Front Chem. 2024;12:1360719. CrossRef PubMed 11. Ahmad I, Khan H, Serdaroğlu G. Physicochemical proper- ties, drug likeness, ADMET, DFT studies, and in vitro anti- oxidant activity of oxindole derivatives. Comput Biol Chem. 2023;104:107861. CrossRef PubMed 12. Kadhim MM, Heravi MRP, Mohammadi-Aghdam S, et al. Investigation of anti-tumor (E)-3-X-oxindole via functionaliza- tion of C20 nano structure: A DFT approach. Comput Theor Chem. 2022;1214:113763. CrossRef 13. Khan M, Yousaf M, Wadood A, et al. Discovery of novel oxin- dole derivatives as potent α-glucosidase inhibitors. Bioorg Med Chem. 2014;22(13):3441-3448. CrossRef PubMed https://doi.org/10.1155/2018/4170372 https://pubmed.ncbi.nlm.nih.gov/30108655/ https://doi.org/10.3390/ijms21176275 https://pubmed.ncbi.nlm.nih.gov/32872570 https://doi.org/10.2991/jegh.k.191028.001 https://pubmed.ncbi.nlm.nih.gov/32175717 https://doi.org/10.2337/diacare.24.8.1460 https://pubmed.ncbi.nlm.nih.gov/11473087 https://doi.org/10.1146/annurev.med.53.082901.103904 https://pubmed.ncbi.nlm.nih.gov/11818473 https://doi.org/10.1016/j.ejphar.2019.172625 https://pubmed.ncbi.nlm.nih.gov/31449807 https://doi.org/10.1016/j.biopha.2021.111842 https://pubmed.ncbi.nlm.nih.gov/34174506 https://doi.org/10.1021/ja00789a070 https://doi:10.1016/j.molstruc.2025.141666 https://doi.org/10.3389/fchem.2024.1360719 https://pubmed.ncbi.nlm.nih.gov/38562526 https://doi.org/10.1016/j.compbiolchem.2023.107861 https://pubmed.ncbi.nlm.nih.gov/37060784 https://doi:10.1016/j.comptc.2022.113763 https://doi.org/10.1016/j.bmc.2014.04.033 https://pubmed.ncbi.nlm.nih.gov/24825482 Rauf et al Drug Target Insights 2025; 19: 17 © 2025 The Authors. Published by AboutScience - www.aboutscience.eu 14. Altowyan MS, Barakat A, Al-Majid AM, et al. Spiroindolone analogues as potential hypoglycemic with dual inhibitory activity on α-amylase and α-glucosidase. Molecules. 2019; 24(12):2342. CrossRef PubMed 15. Rauf A, Khan H, Khan M, et al. In Silico, Swiss ADME, and DFT studies of newly synthesized oxindole derivatives followed by antioxidant studies. J Chem. 2023;2023(1):5553913. CrossRef 16. Huneif MA, Alshehri DB, Alshaibari KS, et al. Design, synthe- sis and bioevaluation of new vanillin hybrid as multitarget inhibitor of α-glucosidase, α-amylase, PTP-1B and DPP4 for the treatment of type-II diabetes. Biomed Pharmacother. 2022;150:113038. CrossRef PubMed 17. Taha M, Ismail NH, Khan A, et al. Synthesis of novel deriva- tives of oxindole, their urease inhibition and molecular dock- ing studies. Bioorg Med Chem Lett. 2015;25(16):3285-3289. CrossRef PubMed 18. Irfan A, Faisal S, Ahmad S, et al. Structure-based virtual screen- ing of furan-1, 3, 4-oxadiazole tethered N-phenylacetamide derivatives as novel class of hTYR and hTYRP1 inhibitors. phar- maceuticals, 2023, 16, (3), 344. CrossRef 19. Nahoum V, Roux G, Anton V, et al. Crystal structures of human pancreatic α-amylase in complex with carbohydrate and pro- teinaceous inhibitors. Biochem J. 2000;346(Pt 1):201-208. CrossRef PubMed 20. Yamamoto K, Miyake H, Kusunoki M, et al. Crystal structures of isomaltase from Saccharomyces cerevisiae and in complex with its competitive inhibitor maltose. FEBS J. 2010;277(20): 4205-4214. CrossRef PubMed 21. Schenone M, Dančík V, Wagner BK, et al. Target identification and mechanism of action in chemical biology and drug discov- ery. Nat Chem Biol. 2013;9(4):232-240. CrossRef PubMed 22. Rindhe SS, Karale BK, Gupta RC, et al. Synthesis, antimicrobial and antioxidant activity of some oxindoles. Indian J Pharm Sci. 2011;73(3):292-296. PubMed 23. Qi Y, Gong H, Wang Z, et al. Discovery of novel oxindole deriva- tives as TRPA1 antagonists with potent analgesic activity for pain treatment. Bioorganic Chemistry 154, 108088. 24. Casirola DM, Ferraris RP. α-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice. Metabolism. 2006;55(6):832-841. CrossRef PubMed 25. Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci. 2012;8(5):899-906. CrossRef PubMed 26. Thilagam E, Parimaladevi B, Kumarappan C, et al. α-Glucosidase and α-amylase inhibitory activity of Senna surattensis. J Acupunct Meridian Stud. 2013;6(1):24-30. CrossRef PubMed 27. de Souza PM, de Oliveira Magalhães P. Application of microbial α-amylase in industry - a review. Braz J Microbiol. 2010;41(4), 850-861. CrossRef PubMed 28. Qin X, Ren L, Yang X, et al. Structures of human pancreatic α-amylase in complex with acarviostatins: implications for drug design against type II diabetes. J Struct Biol. 2011;174(1): 196-202. CrossRef PubMed 29. Jayaraj S, Suresh S, Kadeppagari RK. Amylase inhibitors and their biomedical applications. Stärke. 2013;65(7-8):535-542. CrossRef 30. Azam SS, Uddin R, Wadood A. Structure and dynamics of alpha- glucosidase through molecular dynamics simulation studies. J Mol Liq. 2012;174:58-62. CrossRef https://doi.org/10.3390/molecules24122342 https://pubmed.ncbi.nlm.nih.gov/31242688 https://doi.org/10.1155/2023/5553913 https://doi.org/10.1016/j.biopha.2022.113038 https://pubmed.ncbi.nlm.nih.gov/35658208 https://doi.org/10.1016/j.bmcl.2015.05.069 https://pubmed.ncbi.nlm.nih.gov/26077497 https://doi.org/10.3390/ph16030344 https://doi.org/10.1042/bj3460201 https://pubmed.ncbi.nlm.nih.gov/10657258 https://doi.org/10.1111/j.1742-4658.2010.07810.x https://pubmed.ncbi.nlm.nih.gov/20812985 https://doi.org/10.1038/nchembio.1199 https://pubmed.ncbi.nlm.nih.gov/23508189 https://pubmed.ncbi.nlm.nih.gov/22457553 https://doi.org/10.1016/j.metabol.2006.02.011 https://pubmed.ncbi.nlm.nih.gov/16713445 https://doi.org/10.5114/aoms.2012.31621 https://pubmed.ncbi.nlm.nih.gov/23185202 https://doi.org/10.1016/j.jams.2012.10.005 https://pubmed.ncbi.nlm.nih.gov/23433052 https://doi.org/10.1590/s1517-83822010000400004 https://pubmed.ncbi.nlm.nih.gov/24031565 https://doi.org/10.1016/j.jsb.2010.11.020 https://pubmed.ncbi.nlm.nih.gov/21111049 https://doi.org/10.1002/star.201200194 https://doi.org/10.1016/j.molliq.2012.07.003